Our pipeline
We have an exciting and balanced pipeline underpinned by great science.
Home / Our therapy areas / Our pipeline
Latest quarterly updates
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
183
projects in our pipeline
116
new molecular entities or major life-cycle management in Phase II or Phase III
21
new molecular entities in our late-stage pipeline
4
new molecular entities under review
Includes NME and major life-cycle management projects up to launch in applicable major markets.
Oncology (as of 27 July 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Cardiovascular, Renal and Metabolism (as of 27 July 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Respiratory & Immunology (as of 27 July 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 27 July 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Infectious Disease (as of 27 July 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects